Pavel Majer, Ph.D.
Dr Majer is Group Leader for medicinal Chemistry at the Institute of Organic Chemistry and Biochemistry (IOCB) at the Academy of Sciences of the Czech Republic since 2011. He developed orally active prodrugs of potent inhibitor of GCPII and his team participated in several projects and submitted 4 patent applications.
Dr Majer was Group Leader at Sequoia Pharmaceuticals between 2007 and 2010 where he led medicinal chemistry team on Human Hepatitis C research project, He designed and synthesized inhibitors of protease from Human Hepatitis C Virus (HCV) and Developed series of potent inhibitors of drug-resistant mutants of HCV Protease. Dr Majer was also Senior Scientists At MGI Pharma between 1998 and 2006. During his work at MGI, he designed and synthesized clinical candidates for Neuroprotective therapeutics program (Phase I trial) and developed method for large scale synthesis of Glutamate Carboxy Peptidase II (GCP II) inhibitors.
Dr Majer received his M.S. in Organic Chemistry, summa cum laude from Charles University, Prague, Czech Republic and Ph.D. in Organic Chemistry, Institute of Organic Chemistry and Biochemistry, Czechoslovak Academy of Sciences, Prague, Czech Republic He was Postdoctoral Fellow, and Associate scientist at National Cancer Institute.
Dr Majer Authored 70 papers with 1730 citations and filed 10 patents, with 5 pending patent applications.